Clinical criteria updates for specialty pharmacy

The following clinical criteria documents were endorsed at the October 23, 2020 Clinical Criteria meeting. Access the clinical criteria information here.

 

New clinical criteria effective October 30, 2020

(The following clinical criteria is new.)

• ING-CC-0181: Veklury (remdesivir)

 

Revised clinical criteria effective February 1, 2021

(The following current clinical criteria was revised and might result in services that were previously covered but may now be found to be not medically necessary.)

• ING-CC-0011: Ocrevus (ocrelizumab)

 

Revised clinical criteria effective March 1, 2021

(The following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.)

• ING-CC-0078: Orencia (abatacept)
• ING-CC-0174: Kesimpta (ofatumumab)

 

New clinical criteria effective March 1, 2021

(The following clinical criteria is new.)

• ING-CC-0182: Agents for Iron Deficiency Anemia

 

835-1220-PN-NE